Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 17,950 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $21.07, for a total value of $378,206.50. Following the transaction, the chief financial officer directly owned 115,409 shares of the company’s stock, valued at $2,431,667.63. This trade represents a 13.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Omada Health Stock Up 3.1%
Shares of OMDA stock opened at $22.62 on Thursday. The business has a fifty day simple moving average of $17.00 and a 200 day simple moving average of $14.98. The company has a market cap of $1.34 billion and a P/E ratio of -83.78. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $26.92.
Omada Health (NASDAQ:OMDA – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The firm had revenue of $78.05 million for the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. As a group, equities research analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Omada Health
Analysts Set New Price Targets
OMDA has been the subject of a number of research analyst reports. Weiss Ratings upgraded shares of Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. Barclays boosted their target price on shares of Omada Health from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Canaccord Genuity Group set a $24.00 price target on Omada Health in a research note on Friday, May 8th. BMO Capital Markets cut their price objective on Omada Health from $27.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, March 6th. Finally, Citizens Jmp boosted their price objective on Omada Health from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Omada Health currently has an average rating of “Moderate Buy” and a consensus target price of $22.91.
Get Our Latest Research Report on OMDA
About Omada Health
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
See Also
- Five stocks we like better than Omada Health
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
